- KO-MEN-008 Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
Clinical Trial
KO-MEN-008 Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
A phase 1 study to determine the safety and tolerability of Ziftomenib combinations for the treatment of adult patients with KMT2A-rearranged or NPM1-mutant and relapsed/refractory Acute Myeloid Leukemia
- Circulatory System
- Lymphatic System
- Hematologic Malignancies; Acute Myeloid Leukemia ; NPM1-m; KMT2A-r; Ziftomenib;
Eligibility Criteria
- Adults, age 18 or older Diagnosed with relapsed/refractory acute myeloid leukemia (AML) and documented NPM1-m or KMT2A-r Willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
RESEARCH. INNOVATION. DISCOVERY.